T. Rowe Price Associates’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

T. Rowe Price Associates’s Portfolio DICE Stock Details DICE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-64,449	Closed	-$3M	–	2944
2023 Q2	$3M	Sell	64,449 -3,190,981	-98%	-$110M	﹤0.01%	1343
2023 Q1	$93.3M	Buy	3,255,430 +35,470	+1%	+$1.05M	0.01%	524
2022 Q4	$100M	Buy	3,219,960 +666,503	+26%	+$21.7M	0.02%	492
2022 Q3	$51.8M	Buy	2,553,457 +138,833	+6%	+$2.53M	0.01%	639
2022 Q2	$37.5M	Buy	2,414,624 +270,940	+13%	+$4.66M	﹤0.01%	975
2022 Q1	$41M	Buy	2,143,684 +390,893	+22%	+$6.98M	﹤0.01%	1036
2021 Q4	$44.4M	Buy	1,752,791 +250,542	+17%	+$7.34M	﹤0.01%	1050
2021 Q3	$49.2M	Buy	+1,502,249	New	+$51.2M	﹤0.01%	1016

T. Rowe Price Associates's DICE Position: Q3 2023 in Review

T. Rowe Price Associates sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 64,449 shares — an estimated $3M sold.

T. Rowe Price Associates first reported a position in DICE in Q3 2021 and held it in 8 quarters. The position peaked at $100M in Q4 2022. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

T. Rowe Price Associates reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
T. Rowe Price Associates sold 64,449 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $3M.
T. Rowe Price Associates first reported a position in DICE Therapeutics, Inc. Common Stock in Q3 2021 and held it in 8 quarters.
T. Rowe Price Associates's DICE Therapeutics, Inc. Common Stock position peaked at $100M in Q4 2022.
0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on T. Rowe Price Associates's 13F filing for Q3 2023, filed 14 Nov 2023.